Skip to content

Search
Drug Codes
Coding References
Learn
Tools
Solutions
- Drug Sponsorship
- Drug Market Research
Subscription Options
- Contact Us
- Schedule Consultation

Login
Register

Drug Alerts and Special Reports

Key reimbursement alerts for office-administered drugs — C-Code, J-Code, NDC, and NCCN alerts plus pricing updates, sent on behalf of pharma manufacturers.

Subscribe To Newsletter

09/30/2025

Discover a Sandoz treatment option for neurology patients - 9/30/25

Now Available 09/29/2025

RemunityPRO for Remodulin: Now Available - 9/29/25

09/26/2025

BRUKINSA® (zanubrutinib) 160 mg capsules: Available Soon! - 9/26/25

J-Code 09/24/2025

DATROWAY® (datopotamab deruxtecan-dlnk) permanent J-Code is available - 9/24/25

Now Available 09/23/2025

Now Available: Avyxa's Lutrate® Depot (J1954) - 9/22/25

Now Available 09/08/2025

AVYXA's KYXATA™ (carboplatin) Injection - Now Available - 9/10/25

NCCN 08/23/2025

An NCCN recommendation for the treatment of advanced MSI-H/dMMR CRC - 8/19/25

Now Available 07/31/2025

AVYXA's AVGEMSI™ (gemcitabine) Injection - Now Available - 7/31/25

FDA Approved 07/30/2025

Now Approved – New Indication MONJUVI® (tafasitamab-cxix) - 7/30/25

07/21/2025

Medi-Span Upcoming GPI classification change for IMCIVREE (setmelanotide) - 7/21/25

1 … 456 … 17

No alerts match your filters.

HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, America's Health Insurance Plans, and Blue Cross and Blue Shield Association).

CPT® codes and descriptions are copyright American Medical Association (AMA). All rights reserved

Email us [email protected]

Tools & Lookups

Search
HCPCS Code Lookup
NDC Lookup
Drug Price Lookup
Billing Calculator
Drug Comparative Graphing
Biosimilar Analysis
Part B Reimbursement
All Drug Codes

Coding References

CPT Administration Codes
HCPCS Modifiers
HCPCS Approvals
Medically Unlikely Edits
Place of Service Codes
NDC Listing Errors
SAD Exclusion List
Wastage Guidance (JZ & JW)

Learn

Blog
Newsletter
Bobbi Buell's Newsletter
Glossary
Buy-and-Bill Basics
Biosimilars
505(b)(2)
Drug Shortages

Solutions

Drug Sponsorship
Drug Market Research

Company

About B&B
Subscription Options
Contact Us
Schedule a Consultation
Sitemap

© 2026 BuyandBill.com, a product of Alchemy Healthcare Solutions LLC. All rights reserved

Privacy Policy
Terms of Service

Chart a whole drug class in one screen.

The Comparative Report puts ASP, the Medicare payment limit, WAC and AWP for up to 15 drugs on one timeline. Ten-plus years of monthly history, per HCPCS unit.

Four benchmarks plus the ASP/WAC ratio on the same axis
Prebuilt biosimilar, therapeutic-area and mechanism groups
Index to 100 to compare a $7 drug against a $90 one
Sortable table, reference multiples, saved reports, PDF export

See it in action

Included with BuyandBill Pro for $37/month billed annually.

Trastuzumab class, seven products

7 of 7products fell

▼ 90.0%steepest decline

8.6×price spread

The Comparative Report showing seven trastuzumab products: ASP range $7.73 to $66.27, median $27.16, prices fell 7 of 7, and all seven ASP curves plotted from 2015 to 2026.

Actual published ASP, Jan 2015 to Aug 2026.